LONDON – Cell therapy specialist Reneuron Group plc has sealed a Chinese commercialization and marketing deal, agreeing to an exclusive license for both its CTX treatment for disability caused by stroke and human retinal progenitor cells (hRPC) for treating retinitis pigmentosa, with Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.